J.P. Morgan Sticks to Its Hold Rating for Allogene Therapeutics (ALLO)

By Ryan Adsit

J.P. Morgan analyst Cory Kasimov maintained a Hold rating on Allogene Therapeutics (ALLOResearch Report) yesterday and set a price target of $29.00. The company’s shares closed last Monday at $27.66.

According to TipRanks.com, Kasimov is a 4-star analyst with an average return of 4.7% and a 45.9% success rate. Kasimov covers the Healthcare sector, focusing on stocks such as Global Blood Therapeutics, Ultragenyx Pharmaceutical, and Alexion Pharmaceuticals.

The word on The Street in general, suggests a Strong Buy analyst consensus rating for Allogene Therapeutics with a $34.00 average price target.

See today’s analyst top recommended stocks >>

The company has a one-year high of $35.55 and a one-year low of $23.37. Currently, Allogene Therapeutics has an average volume of 366.4K.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Allogene Therapeutics, Inc. operates as a clinical stage immuno-oncology company pioneering the development and commercialization of genetically engineered allogeneic T cell therapies for the treatment of cancer. The firm develops a pipeline of off-the-shelf T cell product candidates that are designed to target and kill cancer cells.